Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Patient
30%
Overall Survival
24%
Chronic Hepatitis B
23%
Liver Cirrhosis
20%
Inpatient
20%
Hepatitis B Antigen
14%
Liver Transplantation
14%
Neoplasm
13%
Transcatheter Arterial Chemoembolization
13%
Vascular Tissue Neoplasm
13%
Hepatic Portal Vein
13%
Tumor Thrombus
13%
Treatment Response
13%
Bevacizumab
12%
Sorafenib
12%
Cohort Analysis
11%
Hepatitis C Virus
11%
Liver Function
11%
Personal Experience
11%
Hepatic Arterial Infusion
11%
Liver Cancer
11%
Hepatitis B Virus
10%
Cancer Staging
10%
Hazard Ratio
10%
Therapeutic Procedure
9%
Progression Free Survival
9%
Intraarterial Drug Administration
9%
Hepatitis B(e) Antigen
8%
Hepatitis B
8%
Antiviral Therapy
8%
Liver Graft
8%
Lenvatinib
8%
Common Hepatic Artery
8%
Combination Therapy
7%
Chemotherapy
6%
Analysis
6%
Fibrosis
6%
Tumor Necrosis Factor
5%
Association
5%
Fulminant
5%
Disease Exacerbation
5%
Vasculitis
5%
Long Term Survival
5%
Systemic Lupus Erythematosus
5%
Brain Metastasis
5%
Nonalcoholic Fatty Liver
5%
Ledipasvir Plus Sofosbuvir
5%
Tenofovir Disoproxil
5%
Mammalian Target of Rapamycin Inhibitor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
71%
Liver Cell Carcinoma
25%
Overall Survival
22%
Sorafenib
17%
Bevacizumab
15%
Atezolizumab
15%
Chronic Hepatitis B
14%
Liver Cirrhosis
13%
Hepatitis C Virus
12%
Hepatitis B Antigen
10%
Progression Free Survival
10%
Cohort Study
9%
Nonalcoholic Fatty Liver
8%
Tumor Thrombus
8%
Vascular Tumor
8%
Neoplasm
7%
Hepatitis B Virus
6%
microRNA
6%
Cancer Staging
6%
Liver Cancer
6%
Chemotherapy
6%
Ledipasvir Plus Sofosbuvir
5%
Antiviral Therapy
5%
Hepatitis B
5%
Chronic Hepatitis B
5%
Ledipasvir
5%
Tenofovir Alafenamide
5%
Lenvatinib
5%
Sofosbuvir
5%
Tenofovir Disoproxil
5%
Binding Protein
5%
Biological Marker
5%
Antivirus Agent
5%
Immunology and Microbiology
Overall Survival
14%
Atezolizumab
13%
Bevacizumab
13%
Hepatitis B Virus
13%
Hepatitis B
12%
Immunity
10%
Hepatitis B Virus
10%
HBsAg
7%
Progression Free Survival
6%
Hepatitis B
6%
Immunosuppressive Therapy
5%
Gene Mutation
5%
Telomere Length
5%
Reverse Transcriptase
5%
Cytotoxic T-Cell
5%
Protein Glycosylation
5%
Protein Binding
5%
Hepatitis C Virus
5%
Cancer Staging
5%